pI: 5.7785 |
Length (AA): 327 |
MW (Da): 39136 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 257 | 1rjd (A) | 77 | 326 | 27.00 | 0 | 1 | 1.36 | -1.69 |
2 | 324 | 2zwa (A) | 32 | 383 | 33.00 | 0 | 1 | 1.38607 | -0.65 |
10 | 317 | 3iei (A) | 25 | 332 | 34.00 | 0 | 1 | 1.4793 | -1.26 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Oocyst. | Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 24 hs, intra-erythrocytic - 32 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, late trophozoite, Male Gametocyte. | Otto TD PlasmoDB Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | early schizont, late schizont, Ring. | PlasmoDB Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, early trophozoite, Sporozoite, Female Gametocyte. | Otto TD PlasmoDB Zanghi G Lasonder E |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Ortholog group members (OG5_126898)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G02100 | Leucine carboxyl methyltransferase |
Babesia bovis | BBOV_III003160 | hypothetical protein |
Brugia malayi | Bm1_32700 | Leucine carboxyl methyltransferase family protein |
Candida albicans | CaO19.3303 | carboxymethyltransferase |
Candida albicans | CaO19.13734 | carboxy methyl transferase for protein phosphatase 2A |
Candida albicans | CaO19.6377 | carboxy methyl transferase for protein phosphatase 2A |
Candida albicans | CaO19.10813 | carboxymethyltransferase |
Caenorhabditis elegans | CELE_B0285.4 | Protein B0285.4 |
Dictyostelium discoideum | DDB_G0288271 | leucine carboxyl methyltransferase |
Drosophila melanogaster | Dmel_CG3793 | CG3793 gene product from transcript CG3793-RB |
Echinococcus granulosus | EgrG_000120900 | leucine carboxyl methyltransferase 1 |
Echinococcus multilocularis | EmuJ_000120900 | leucine carboxyl methyltransferase 1 |
Giardia lamblia | GL50803_10516 | Leucine carboxyl methyltransferase |
Homo sapiens | ENSG00000162971 | tRNA-yW synthesizing protein 5 |
Homo sapiens | 9836 | leucine carboxyl methyltransferase 2 |
Leishmania braziliensis | LbrM.35.0150 | leucine carboxyl methyltransferase, putative |
Leishmania braziliensis | LbrM.34.2850 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_352990.1 | Leucine carboxyl methyltransferase/Cupin-like domain containing protein, putative |
Leishmania donovani | LdBPK_360090.1 | leucine carboxyl methyltransferase, putative |
Leishmania infantum | LinJ.36.0090 | leucine carboxyl methyltransferase, putative |
Leishmania infantum | LinJ.35.2990 | hypothetical protein, conserved |
Leishmania major | LmjF.36.0080 | leucine carboxyl methyltransferase, putative |
Leishmania major | LmjF.35.2940 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.34.2940 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.36.0080 | leucine carboxyl methyltransferase, putative |
Loa Loa (eye worm) | LOAG_05792 | hypothetical protein |
Loa Loa (eye worm) | LOAG_11076 | leucine carboxyl methyltransferase |
Mus musculus | ENSMUSG00000074890 | leucine carboxyl methyltransferase 2 |
Mus musculus | ENSMUSG00000030763 | leucine carboxyl methyltransferase 1 |
Mus musculus | ENSMUSG00000048495 | tRNA-yW synthesizing protein 5 |
Neospora caninum | NCLIV_051310 | Leucine carboxyl methyltransferase, related |
Oryza sativa | 4340066 | Os06g0140100 |
Onchocerca volvulus | OVOC3030 | Putative leucine carboxyl methyltransferase 1 |
Plasmodium berghei | PBANKA_1303600 | leucine carboxyl methyltransferase, putative |
Plasmodium falciparum | PF3D7_1439700 | leucine carboxyl methyltransferase, putative |
Plasmodium knowlesi | PKNH_1242600 | leucine carboxyl methyltransferase, putative |
Plasmodium vivax | PVX_118505 | leucine carboxyl methyltransferase, putative |
Plasmodium yoelii | PY00828 | unknown protein-related |
Saccharomyces cerevisiae | YDR435C | Ppm1p |
Saccharomyces cerevisiae | YOL141W | Ppm2p |
Schistosoma japonicum | Sjp_0204500 | ko:K00599 leucine carboxyl methyltransferase 1 [EC:2.1.1.-], putative |
Schistosoma mansoni | Smp_124860 | hypothetical protein |
Schmidtea mediterranea | mk4.002399.01 | |
Schmidtea mediterranea | mk4.027262.00 | Probable leucine carboxyl methyltransferase 1 |
Schmidtea mediterranea | mk4.009380.01 | tRNA wybutosine-synthesizing protein 5 |
Schmidtea mediterranea | mk4.001492.01 | |
Schmidtea mediterranea | mk4.001492.02 | tRNA wybutosine-synthesizing protein 4 |
Schmidtea mediterranea | mk4.003235.01 | Probable leucine carboxyl methyltransferase 1 |
Trypanosoma brucei gambiense | Tbg972.10.5490 | leucine carboxyl methyltransferase, putative |
Trypanosoma brucei gambiense | Tbg972.9.7830 | hypothetical protein, conserved |
Trypanosoma brucei | Tb10.v4.0036 | leucine carboxyl methyltransferase, putative |
Trypanosoma brucei | Tb927.10.4460 | leucine carboxyl methyltransferase, putative |
Trypanosoma brucei | Tb927.9.12780 | Leucine carboxyl methyltransferase/Cupin-like domain containing protein, putative |
Trypanosoma congolense | TcIL3000_10_3660 | leucine carboxyl methyltransferase, putative |
Trypanosoma congolense | TcIL3000_9_5290 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.510659.130 | Leucine carboxyl methyltransferase/Cupin-like domain containing protein, putative |
Trypanosoma cruzi | TcCLB.509757.20 | leucine carboxyl methyltransferase, putative |
Trypanosoma cruzi | TcCLB.508625.120 | leucine carboxyl methyltransferase, putative |
Trypanosoma cruzi | TcCLB.508463.29 | Leucine carboxyl methyltransferase/Cupin-like domain containing protein, putative |
Toxoplasma gondii | TGME49_237570 | leucine carboxyl methyltransferase |
Theileria parva | TP03_0904 | hypothetical protein |
Theileria parva | TP02_0471 | hypothetical protein, conserved |
Theileria parva | TP04_0135 | hypothetical protein, conserved |
Theileria parva | TP04_0130 | hypothetical protein |
Theileria parva | TP04_0133 | hypothetical protein |
Theileria parva | TP04_0131 | hypothetical protein |
Theileria parva | TP04_0132 | hypothetical protein |
Theileria parva | TP04_0134 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_044530 | leucine carboxyl methyltransferase, putative |
Trichomonas vaginalis | TVAG_184240 | leucine carboxyl methyltransferase, putative |
Trichomonas vaginalis | TVAG_003240 | leucine carboxyl methyltransferase, putative |
Trichomonas vaginalis | TVAG_474040 | leucine carboxyl methyltransferase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.211.3730 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.3730 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.3730 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.211.3730 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1303600 | Plasmodium berghei | Essential | plasmo |
TGME49_237570 | Toxoplasma gondii | Probably non-essential | sidik |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.